Some evidence shows that only the combined use of PIK3CA inhibitor (BKM120) and PARP inhibitor (olaparib) may prove effective in treating ovarian cancers with a wider range of cancer-associated genetic alterations [72]. Here, PIK3CA is linked to ovarian carcinoma.